The global "polycystic ovary syndrome market" size is estimated to reach at a high CAGR during the forecast period 2022-2029
Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes irregular or prolonged menstrual cycles or excess male hormone levels. Presently, there is no cure for PCOS. However, various medications are used to regulate the menstrual cycle and to manage symptoms of PCOS.
The global polycystic ovary syndrome market growth is driven by the increase in the prevalence of PCOS, a rise in awareness among the patient population, and increased adoption of combination therapy drive the polycystic ovarian syndrome treatment market growth. In addition, easy accessibility to PCOS therapeutics, a rise in demand for PCOS medications, and technological advancements for PCOS detection influence the market growth.
Growing initiatives by private and government firms to increase awareness about the disease coupled with the increase in the prevalence of PCOS are expected to drive the growth in the forecast period
PCOS is a most common hormonal endocrine disorder that affects women of childbearing age (15 to 49 years). By the Centers for Disease Control & Prevention (CDC), PCOS is the most common cause of female infertility. Also, as per a study published in September 2019, the prevalence of polycystic ovarian syndrome in adolescents, based on the Rotterdam criteria, was found to be 11.04%, based on the National Institute of Health’s criteria was 3.39%, and based on the Androgen Excess and Polycystic Ovary Syndrome Society was 8.03%, worldwide. The increasing burden of PCOS and the lack of targeted therapy for PCOS in the market create a need to develop treatment therapies. The players in the market are currently focusing on the unmet need of the market and on strengthening their pipelines to leverage the opportunities; the commercialization of these robust pipelines is expected to propel market growth. For instance, Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women’s health, currently has the molecule HSD17B5 inhibitor in its pipeline. This enzyme is overexpressed in the adipose tissue of PCOS patients. These developments are expected to raise the market over the forecast period.
Moreover, there have been many initiatives by private and government firms to increase awareness about the disease, which is also expected to drive the market. For instance, in June 2020, the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Diabetes and Digestive and Kidney Diseases funded a study on ‘Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis’ and reported that polycystic ovary syndrome might have at least two different subtypes.
Lack of drug approval from the FDA and possible side effects associated with generics could hamper the growth of the market
Lack of approved drugs directly targeting PCOS disease drugs. The side effects associated with generics include nausea, vomiting, stomach pain, diarrhea and loss of appetite.
Supply Chain Analysis
COVID-19 Impact Analysis
Many gynecological procedures and unnecessary treatment have been postponed owing to the current pandemic. Furthermore, non-COVID-19 related research is being delayed by multiple companies, leading to delayed product launches. Some disruptions in sourcing raw materials from impacted countries, such as China, were observed in early 2020, but such disorders are unlikely to affect going forward. However, as previous restrictions are now being relaxed in several countries, the market growth will also resume.
The laparoscopic ovarian drilling segment is expected to hold the largest share in this market segment
Laparoscopic ovarian drilling is the most common surgery performed by doctors in critical conditions. Since women's fertility problems are quite predominant because of PCOS, and response to medications weakens over time, the surgery performed via a thin microscope through the abdomen is preferred across the geography. As per the study published in 2019 by the Department of Gynecology and Obstetrics, in major hospitals in France, after laparoscopic drilling, 47.4% (137 patients) had a pregnancy, and 51.8% (71 patients) of these were spontaneous; also 16.6% (48 patients) of the women had at least two pregnancies after drilling, and 56.3% (27 patients) of these were spontaneous. The study suggested a high success rate in laparoscopic drilling in women, which is why it is most preferred. Moreover, the cost-effective procedures drive patients toward this surgical procedure for easy treatment of the disease. Hence, it is estimated to have a major share over the forecast period.
However, the COVID-19 pandemic has had ramifications for ways of working of various surgical procedures, including laparoscopic ovarian drilling. In May 2020, University of Birmingham Experts at the University of Birmingham-led NIHR Global Research Health Unit on Global Surgery published their findings that the patients undergoing surgery after contracting coronavirus are at increased risk of postoperative death and are recommended to avoid all non-emergent surgeries. But, later, the regulatory bodies, to keep the normal surgical procedures going on, imposed a few guidelines specific to each speciality that have to be implemented and followed for the surgeons to continue providing safe and effective care to their patients during the COVID-19 pandemic. These issued guidelines have allowed healthcare providers to resume their surgery practices. Thus, it is expected that the laparoscopic ovarian drilling procedures are also likely to regain their normal growth in the future.
North America region holds the largest market share of the global polycystic ovary syndrome market
Obesity, considered one of the major risk factors for PCOS, has seen an upsurge during the pandemic. In September 2020, the Centers for Disease Control and Prevention (CDC) notified that adult obesity is increasing, and racial and ethnic disparities persist due to the current circumstances of work from home, lesser physical activities, and financial and other stress among the adult population. The CDC stated that obesity remains high, and currently, twelve states have an adult obesity prevalence at or above 35 %, including Alabama, Arkansas, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia. The data by CDC revealed that there is a high prevalence of obesity in North American countries, which is going to increase the risk of PCOS and is anticipated to offer positive growth to the market.
The United States and Canada are highly advanced in procuring new technology and early release of drugs in the market. This region has a major player base and a strong product pipeline to increase the market growth. For instance, AbbVie, a United States-headquartered company, currently has Elagolix (ABT-620), an oral gonadotropin-releasing hormone antagonist studied to treat endometriosis and PCOS. In November 2019, the University of Illinois at Chicago funded clinical research to study the effect of salsalate administration on the ovarian capacity to secrete androgen and on insulin sensitivity in PCOS. The need to ease the treatment and procedures has evolved significantly in the past decade, pushing several R&D investments and venture partners funding for pharmaceutical companies in this region, thus driving the market growth.
The global polycystic ovary syndrome market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, Novartis, Takeda Pharmaceutical Company Limited, Abbvie, Ferring BV, Merck KGaA and EffRx, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, In Jan 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome, which is expected to drive the market during the forecast period.
Global Polycystic Ovary Syndrome Market – Key Companies to Watch
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: PROVERA is a medicine that contains medroxyprogesterone acetate, a progestin hormone.
Acute Coronary Syndrome Market
Chronic fatigue syndrome Market